Kevin Koch
President and CEO, Director · Edgewise Therapeutics, Inc.
- 2025
- Aug 14, 2026
- 3
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Kevin Koch files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Alan J. Russell - $10.25M in EWTX purchases and sales in the last 12 months
- Joanne M. Donovan - $4.62M in EWTX purchases and sales in the last 12 months
- Badreddin Edris - $3.40M in EWTX purchases and sales in the last 12 months
- Behrad Derakhshan - $223K in EWTX purchases and sales in the last 12 months
- John R. Moore - $220K in EWTX purchases and sales in the last 12 months
- Jonathan C. Fox - $199K in EWTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Kevin Koch?
Kevin Koch is a corporate insider, tracked as President and CEO, Director of Edgewise Therapeutics, Inc. (EWTX). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Kevin Koch submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Kevin Koch been buying or selling stock?
Recorded transactions: 0 open-market purchases and 5 open-market sales ($962K) across all tracked filings.
